Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience
Open Access
Abstract
(1) Background: NF2-related schwannomatosis, characterized by the development of bilateral vestibular schwannomas, often necessitates varied treatment approaches. Bevacizumab, though widely utilized, demonstrates variable effectiveness on hearing and tumor growth. At the same time, (serious) adverse events have been frequently reported. (2) Methods: A single center retrospective study was conducted, on NF2-related schwannomatosis patients treated with bevacizumab from 2013 to 2023, with the aim to assess treatment-related and clinical outcomes. Outcomes of interest comprised hearing, radiologic response, symptoms, and adverse events. (3) Results: Seventeen patients received 7.5 mg/kg bevacizumab for 7.1 months. Following treatment, 40% of the patients experienced hearing improvement, 53%, stable hearing, and 7%, hearing loss. Vestibular schwannoma regression occurred in 31%, and 69% remained stable. Further symptomatic improvement was reported by 41%, stable symptoms by 47%, and worsened symptoms by 12%. Treatment discontinuation due to adverse events was observed in 29% of cases. Hypertension (82%) and fatigue (29%) were most frequently reported, with no occurrences of grade 4/5 toxicities. (4) Conclusion: Supporting previous studies, bevacizumab demonstrated positive effects on hearing, tumor control, and symptoms in NF2-related schwannomatosis, albeit with common adverse events. Therefore, careful consideration of an appropriate management strategy is warranted.Keywords
This publication has 36 references indexed in Scilit:
- Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendationGenetics in Medicine, 2022
- Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysisJournal of Neuro-Oncology, 2022
- Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohortJournal of Neuro-Oncology, 2016
- Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2Journal of Neuro-Oncology, 2015
- Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2European Archives of Oto-Rhino-Laryngology, 2015
- The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2European Archives of Oto-Rhino-Laryngology, 2014
- Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patientsCancer Chemotherapy and Pharmacology, 2014
- Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2American Journal of Medical Genetics Part A, 2011
- Neurofibromatosis type 2The Lancet, 2009
- Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannomaJournal of Neuro-Oncology, 2009